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ABSTRACT
Huntingtin is a large membrane-associated scaffolding protein that
associates with endocytic and exocytic vesicles and modulates their
trafficking along cytoskeletal tracks. Although the progression of
Huntington’s disease is linked to toxic accumulation of mutant
huntingtin protein, loss of wild-type huntingtin function might also
contribute to neuronal cell death, but its precise function is not well
understood. Therefore, we investigated the molecular role of
huntingtin in exocytosis and observed that huntingtin knockdown in
HeLa cells causes a delay in endoplasmic reticulum (ER)-to-Golgi
transport and a reduction in the number of cargo vesicles leaving the
trans-Golgi network. In addition, we found that huntingtin is required
for secretory vesicle fusion at the plasma membrane. Similar defects
in the early exocytic pathway were observed in primary fibroblasts
from homozygous Htt140Q/140Q knock-in mice, which have the
expansion inserted into the mouse huntingtin gene so lack wild-type
huntingtin expression. Interestingly, heterozygous fibroblasts from a
Huntington’s disease patient with a 180Q expansion displayed no
obvious defects in the early secretory pathway. Thus, our results
highlight the requirement for wild-type huntingtin at distinct steps
along the secretory pathway.
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INTRODUCTION
Huntington’s disease (HD) is an autosomal dominant
neurodegenerative disorder that is caused by a polyglutamine (polyQ)
repeat expansion at the N-terminus of the protein huntingtin (HTT)
(DiFiglia et al., 1997; Imarisio et al., 2008). The age of disease onset
and the rate of aggregation depend on the length of the polyQ
expansion; for example, 40-50 repeats cause adult-onset HD, whereas
a large number of repeats (e.g. 180) leads to juvenile forms of the
disease (Squitieri et al., 2002; Snell et al., 1993). HD progression is
complex and clearly involves a gain of toxic functions of the mutant
protein leading to the formation of protein aggregates, the
accumulation of damaged mitochondria, proteasome and autophagy
dysfunction, and finally neuronal cell death (Borrell-Pagès et al.,
2006). Hence, a detailed analysis of the diverse cellular functions of
wild-type huntingtin is required to understand the exact contribution(s)
that loss of wild-type huntingtin plays in disease progression (Schulte
and Littleton, 2011; Caviston and Holzbaur, 2009).
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In mammals, loss of wild-type huntingtin is embryonic lethal,
highlighting the essential cellular role of this protein (Nasir et al.,
1995; Duyao et al., 1995; Zeitlin et al., 1995). Huntingtin is a large
scaffold protein that associates with a variety of cellular binding
partners (Shirasaki et al., 2012), which mediate huntingtin’s multiple
roles in intracellular transport and membrane trafficking (Caviston
and Holzbaur, 2009). For example, huntingtin-associated protein 1
(HAP1) links huntingtin to both plus-end-directed kinesin and
minus-end-directed dynein motor proteins, emphasising the
importance of huntingtin for anterograde and retrograde axonal
transport along microtubule tracks (Li et al., 1995; Li and Li, 2005;
Engelender et al., 1997). Furthermore, huntingtin can also associate
through optineurin with the actin-based motor myosin VI, and thus
huntingtin is in the unique position to coordinate transport along the
microtubule and actin cytoskeleton (Hattula and Peränen, 2000;
Sahlender et al., 2005).
Transport defects become noticeable during HD progression
when reduced levels of brain-derived neurotrophic factor (BDNF)
are transported and secreted by cortical neurons and astrocytes.
Consequently, less BDNF is taken up by striatal neurons, and this
might play an important role in the selective neuronal vulnerability
and degeneration associated with this disease (Wang et al., 2012).
Thus, in this study, we have used a novel fluorescent reporter assay
to investigate the molecular role of huntingtin in protein secretion
using HeLa cells expressing HTT siRNA and homozygous primary
embryonic fibroblasts isolated from the Htt140Q/140Q knock-in (KI)
mouse as well as primary fibroblasts from an individual with HD
who is heterozygous for 180Q at the HTT locus (HTT+/180Q). Our
results demonstrate that wild-type huntingtin is required in the
secretory pathway in HeLa cells for vesicle transport from the
endoplasmic reticulum (ER) to the Golgi complex, for the
formation and delivery of vesicles from the Golgi to the plasma
membrane, and for vesicle fusion with the plasma membrane.
Comparing protein secretion in HTT-siRNA-treated cells,
homozygous Htt140Q/140Q mouse embryonic fibroblasts (MEFs) and
heterozygous HTT+/180Q patient fibroblasts suggests that one copy
of wild-type huntingtin is sufficient to maintain delivery of
secretory cargo between the ER and the Golgi complex in
fibroblasts. Interestingly, secretion is not affected by the toxic gain
of function of mutant huntingtin protein in heterozygous patient
fibroblasts.
RESULTS
Huntingtin and dynein function is required in the early
secretory pathway
To probe the role(s) of wild-type huntingtin in the secretory
pathway, we used a HeLa cell line (termed HeLa C1) stably
expressing a constitutively secreted GFP-tagged variant of the
human growth hormone (hGH). This reporter construct (GFP-hGH)
is attached to multiple aggregation domains, which cause the newly
synthesised GFP-hGH protein to aggregate and be retained in the
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ER. Treating the cells with a small ligand (AP21998) reverses the
aggregation, resulting in a synchronous release of GFP-hGH from
the ER to the Golgi complex and then on to the plasma membrane
for exocytosis (Bond et al., 2011; Gordon et al., 2010). This tightly
regulated secretion assay provides an elegant method for visualising
these main stages of constitutive secretion by live-cell time-lapse
fluorescence microscopy.
First, we investigated the involvement of huntingtin in the
delivery of newly synthesised proteins from the ER to the Golgi
complex. HeLa C1 cells were either mock-treated or transfected
with siRNA targeting HTT. After confirming huntingtin protein
depletion by immunoblotting (Fig. 1D), cells were imaged using
live-cell spinning-disk microscopy. The Golgi region was visualised
by expressing the RFP-tagged Golgi marker GalT (beta-1,4-
galactosyltransferase-I). Still movie images depicting the transfer of
the GFP-hGH from the ER (0 minutes) to the Golgi (15 minutes)
after AP21998 ligand addition are shown (Fig. 1A). The rate of
reporter transport from the ER to the Golgi was quantified by
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TRANSLATIONAL IMPACT
Clinical issue
Huntington’s disease (HD) is an incurable, autosomal dominant
neurodegenerative condition characterised by late-onset motor, cognitive
and psychiatric symptoms. HD is linked to mutations in the HTT gene
that lead to an extended polyglutamine repeat at the N-terminus of the
huntingtin protein. This mutant protein is prone to aggregation and is
thereby cytotoxic for neurons, leading to neuronal loss in the striatum
and cortex. The huntingtin protein is ubiquitously expressed in the brain
and has multiple roles in cellular membrane trafficking, including
anterograde axonal transport of neurotrophic factors [such as brain-
derived neurotrophic factor (BDNF)] for release from cortical neurons.
During HD progression, transport defects become noticeable, with
decreased secretion of BDNF by cortical neurons and astrocytes, and
consequently reduced uptake of BDNF by striatal neurons; this might
play an important role in the selective neuronal vulnerability and
degeneration associated with this disease.
Results
To investigate the role of wild-type huntingtin in protein secretion, the
authors use a combination of tissue culture cell lines, including primary
fibroblasts isolated from homozygous Htt140Q/140Q knock-in mice, HTT-
knockdown human HeLa cells and primary fibroblasts obtained from a
heterozygous individual with HD (HTT+/180Q). They use a unique
secretory assay that allows dissection of the exact step(s) that require
the huntingtin protein during protein secretion. The authors demonstrate
that wild-type huntingtin is required for vesicle transport from the
endoplasmic reticulum (ER) to the Golgi complex, for the formation and
delivery of vesicles from the Golgi to the plasma membrane, and for
vesicle fusion with the plasma membrane. The complete loss of wild-type
huntingtin in homozygous Htt140Q/140Q knock-in mouse fibroblasts and
HTT siRNA knockdown in HeLa cells has a significant impact on protein
secretion. In heterozygous HD human fibroblasts (HTT+/180Q), one copy
of wild-type huntingtin is sufficient to support cargo delivery from the ER
to the plasma membrane.
Implications and future directions
It is well-established that HD progression is linked to the toxic
accumulation of mutant huntingtin protein; however, loss of wild-type
huntingtin function might also contribute to neuronal cell death. Here, the
authors demonstrate the requirement for wild-type huntingtin at several
steps along the secretory pathway. Although in heterozygous HD human
fibroblasts one copy of wild-type huntingtin is sufficient to maintain
protein secretion, in neuronal cells the distances for cargo transport from
the ER to the Golgi and then to the plasma membrane are extremely
long. Thus, a slight impairment in the efficiency of cargo delivery is likely
to result in major defects in protein secretion, which might contribute to
the reduced BDNF secretion observed in HD. This study suggests a
crucial function for wild-type huntingtin in the secretory pathway that
cannot be fulfilled by the mutant protein and, therefore, these results
could have important implications for therapies that aim to reduce
huntingtin levels. 
Fig. 1. Depletion of huntingtin and its binding partner dynein
intermediate chain (DIC) reduces the rate of ER-to-Golgi transport.
(A) To follow transport of the GFP reporter from the ER to Golgi, HeLa C1
cells stably expressing the GFP-hGH reporter construct (green) and
transiently transfected with GalT-mRFP (red) to mark the Golgi were fixed at
the indicated times after AP21998 ligand addition and processed for
immunofluorescence microscopy. (B) To analyse the rate of reporter
movement from ER to Golgi, HeLa C1 cells that were either mock-treated or
treated with HTT or DIC siRNA were imaged by live-cell spinning-disk
microscopy after ligand addition. Volocity imaging software was used to
calculate the rate of accumulation of GFP reporter in the Golgi region over
time in these cells. (C) Graph depicting the average rate of ER-to-Golgi
reporter transport in huntingtin-depleted cells as a percentage of mock.
Huntingtin depletion resulted in a ~45% decrease in ER-to-Golgi transfer rate
compared with control. 59 cells from three independent knockdown
experiments were analysed using the unpaired Student’s t-test. Values are
means ± s.e.m. (D) Representative immunoblot using antibodies against
huntingtin and α-tubulin as a loading control demonstrates huntingtin protein
depletion. (E) Depletion of the huntingtin binding partner DIC results in a
~30% decrease in ER-to-Golgi transfer compared with control. 93 cells from
five independent knockdown experiments were analysed. (F) Representative
immunoblot using antibodies against DIC and α-tubulin as a loading control
















measuring the accumulation of fluorescent reporter intensity in the
Golgi region as a percentage of the total fluorescence intensity over
time (Fig. 1B). Interestingly, huntingtin depletion led to a significant
reduction (~45%) in ER-to-Golgi transport (Fig. 1C), when
compared with mock control cells, suggesting a kinetic delay rather
than a complete block of cargo transfer from the ER to the Golgi
(see supplementary material Movie 1). Deconvolving of the siRNA
SMARTpool against HTT revealed that the individual siRNA oligo
2 leads to efficient knockdown (similar to the SMARTpool)
resulting in a significant reduction in ER-to-Golgi transport (see
supplementary material Fig. S1).
Dynein, a microtubule-based motor protein and huntingtin-
interacting protein, has been shown to mediate cargo transport
between the ER and Golgi complex (Gupta et al., 2008; Palmer et
al., 2009; Presley et al., 1997; Roghi and Allan, 1999). To
determine whether compromising dynein activity affects the ER-
to-Golgi GFP-hGH transport assay, we performed siRNA
knockdown of the dynein intermediate chain (DIC), which
mediates huntingtin-dynein interaction. Loss of dynein
intermediate chain causes a 35-40% reduction in transport of GFP-
hGH from the ER to the Golgi complex (Fig. 1B,E). This is
comparable to the results observed in cells treated with HTT
siRNA and suggests that huntingtin and dynein might form a
functional complex that mediates secretory vesicle transport along
microtubules in the early secretory pathway.
Huntingtin is involved in vesicle delivery from the Golgi
complex to the plasma membrane
To determine whether huntingtin depletion affects the number of
GFP-hGH-reporter-containing vesicles leaving the Golgi, a series of
1-minute, confocal spinning-disk time-lapse movies was used to
quantify the number of cargo-filled vesicles travelling through
defined 6×6-μm regions between the trans-Golgi network and the
plasma membrane (Fig. 2A). siRNA knockdown of huntingtin
(Fig. 2C) led to a ~40% reduction in the number of secretory
vesicles leaving the Golgi apparatus when compared with mock-
treated cells (Fig. 2B). Previously, we showed that ER-to-Golgi
transport is not a rate-limiting step in the overall secretory process
and a kinetic delay in this early secretory pathway does not always
have a knock-on effect on post-Golgi trafficking (Bond et al., 2011).
Thus, we propose a direct role for huntingtin in the formation of
secretory vesicles at the trans-Golgi network.
Depletion of huntingtin reduces the number of exocytic
vesicle fusion events at the plasma membrane
To examine the role of huntingtin at the plasma membrane in live
cells, we used TIRF (total internal reflection fluorescence)
microscopy, which allows selective imaging of a ~100 nm region
beneath the plasma membrane. Due to the high signal-to-noise ratio,
single fusion events of fluorescent secretory cargo vesicles with the
plasma membrane can be visualised as a short flash in the TIRF
field. Loss of wild-type huntingtin resulted in a significant decrease
of ~50% in the total number of fusion events as compared with
control cells (Fig. 3A, see supplementary material Movie 2) and an
observed accumulation of secretory vesicles underneath the plasma
membrane (Fig. 3B). Indeed, quantitation of the total area in the
TIRF field occupied by secretory vesicles captured at intervals
between 25 and 59 minutes after ligand addition revealed a
significant increase in docked vesicles in huntingtin-knockdown
cells when compared with mock-treated cells (Fig. 3B,C). These
results clearly demonstrate a direct role for huntingtin in the final
fusion events during exocytosis.
Homozygous primary Htt140Q/140Q MEFs, but not heterozygous
HD patient fibroblasts, have a delay in cargo transport
between the ER and Golgi
Finally, we analysed the secretory pathway in human fibroblasts
from a healthy control (GM23976A) and an individual with
juvenile-onset HD [heterozygous for an expanded polyQ tract of
180Q (HTT+/180Q); GM09197B], and in primary MEFs isolated from
wild-type mice (typically around E17/18) and homozygous
Htt140Q/140Q KI mice. The human and mouse fibroblasts were
transiently transfected with the GFP-hGH reporter construct and the
amount of this reporter molecule in the Golgi area was analysed at
0, 15 and 30 minutes after AP21998 ligand addition. As shown in
Fig. 4A, there was no significant difference in reporter movement
from the ER to the Golgi in control compared with heterozygous
HTT+/180Q patient fibroblasts. However, significantly less cargo
accumulated in the Golgi 15 minutes after ligand addition in
homozygote Htt140Q/140Q KI MEFs when compared with wild-type
MEFs (Fig. 4B). Thus, efficient cargo transport in the early secretory
pathway requires at least one copy of wild-type huntingtin, which
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Fig. 2. Huntingtin depletion leads to a reduction in the number of
vesicles travelling between the Golgi and plasma membrane. (A) In
HeLa C1 cells treated with HTT siRNA, live-cell spinning-disk microscopy
was used to capture continuous 1-minute movies at defined intervals
between 25 and 59 minutes after ligand addition. The total number of
vesicles travelling through ten 6×6-μm areas (white boxes) between the
Golgi complex and the plasma membrane was quantified over the course of
18 one-minute movies using Imaris vesicle-tracking software. (B) Analysis of
1800 regions of >630 cells from five independent knockdown experiments
indicates that huntingtin depletion results in reduced numbers of secretory
vesicles leaving the Golgi when compared with mock-treated cells.
(C) Representative immunoblot demonstrating huntingtin protein knockdown

















cannot be replaced by the overexpression of mutant 140Q huntingtin
in primary MEFs. At least in fibroblasts, the presence of one copy
of mutant huntingtin with a 180Q tract does not seem to disrupt
cargo transport in the secretory pathway.
DISCUSSION
Huntingtin has multiple roles in cellular membrane trafficking and
associates with microtubule-based kinesin and dynein motor
proteins, but is also linked via its interacting protein optineurin with
the actin-associated motor myosin VI (Hattula and Peränen, 2000;
Sahlender et al., 2005; Bond et al., 2011). Using a microscopy-based
secretion assay in HeLa cells, we have established that huntingtin is
required for precise stages of protein secretion: for ER-to-Golgi
transport as well as vesicle fusion at the cell surface. In addition, our
data suggest that huntingtin might be required for the formation of
exocytic vesicles at the trans-Golgi complex and trafficking of
vesicles from the Golgi to the plasma membrane. Dynein has also
been implicated in the trafficking between the ER and Golgi
complex (Lee et al., 2004; Lippincott-Schwartz et al., 1995; Stauber
et al., 2006) and kinesin motors for post-Golgi transport to the
plasma membrane (Kreitzer et al., 2000). Huntingtin interacts with
dynein and kinesin via HAP1 (Harjes and Wanker, 2003; Li and Li,
2004) and directly binds to dynein intermediate chain (Caviston et
al., 2007); thus, huntingtin might function as a key factor along the
secretory pathway by promoting the association of vesicles with the
cytoskeleton and by acting as a molecular switch via its respective
interactions with these microtubule-based motor proteins.
Huntingtin function in the final fusion events at the plasma
membrane could involve its binding partner optineurin, a myosin-
VI-associated cargo adaptor. The importance of a functional
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Fig. 3. Huntingtin loss reduces the number of vesicle fusion events and
increases the number of docked vesicles at the plasma membrane.
(A) Vesicle fusion events in mock or huntingtin-depleted HeLa C1 cells were
monitored by live-cell TIRF microscopy at 5-minute intervals between 25 and
59 minutes after ligand addition. Huntingtin depletion causes a significant
decrease of 50% in average number of vesicle fusion events at the plasma
membrane. 170 cells from four independent knockdown experiments
performed in duplicate or triplicate were analysed using the Student’s t-test;
values are means ± s.e.m. (B) In mock or huntingtin-depleted HeLa C1 cells,
the total area in the TIRF field occupied by fluorescent vesicles in single-
plane images taken at specific intervals between 25 and 60 minutes after
AP21998 ligand addition was calculated using Volocity analysis software.
Huntingtin knockdown results in a significant increase in the area occupied
by docked vesicles as compared with mock. 170 cells from four independent
knockdown experiments (as used in the TIRF fusion assay) were analysed
using the Student’s t-test; values are means ± s.e.m. (C) Vesicles in the TIRF
field at the base of mock and huntingtin-depleted cells. *P≤0.05; ***P≤0.001.
Fig. 4. ER-to-Golgi transport of a fluorescent reporter is reduced in
homozygous Htt140Q/140Q KI MEFs but not in heterozygous patient
fibroblasts with a 180Q expansion. (A) Human fibroblasts from a healthy
control and a patient with juvenile-onset HD (HTT+/180Q) were transiently
transfected with the GFP-hGH reporter construct. Cells were untreated or
treated with the ligand AP21998 for 0, 15 and 30 minutes, fixed and stained
with antibodies to GFP and the Golgi protein GM130. The amount of
fluorescent reporter present in the Golgi region was quantified in confocal
images using Volocity image-analysis software in >350 cells from four
independent experiments and is illustrated as a scatter plot with the line
representing the mean. There was no significant difference in reporter
movement from the ER to Golgi in HD patient fibroblasts compared with
control. (B) Mouse embryonic fibroblasts (MEFs) were isolated from wild-type
and Htt140Q/140Q knock-in mice at E17/18 and transiently transfected with the
GFP-hGH reporter construct. At 0, 15 and 30 minutes after AP21998 ligand
addition, GFP and GM130 colocalisation images were analysed by
calculating the Pearson’s coefficient using Volocity image-analysis software.
Compared with wild-type MEFs, significantly less cargo accumulated in the
Golgi of homozygous Htt140Q/140Q knock-in MEFs in >120 cells in four
independent experiments and is illustrated as a box-and-whisker plot. The
box represents the median, 25th and 75th percentiles and whiskers
represent the maximum and minimum. A one-way ANOVA followed by a
post-hoc Bonferroni multiple comparison test was conducted as a statistical
















complex of huntingtin, myosin VI and optineurin during vesicle
fusion at the plasma membrane is supported by the fact that the
absence of any of these proteins results in a very similar phenotype:
a reduction in the number of vesicle fusion events at the plasma
membrane and an accumulation of vesicles beneath the plasma
membrane (Bond et al., 2011; and this work).
HeLa C1 cells are an ideal system to visualise cargo transport in
the secretory pathway. The movement of large, bright exocytic
vesicles between the ER and Golgi complex (see supplementary
material Movie 2) and then to the plasma membrane can be
followed by live-cell microscopy. The large size and content of
fluorescent cargo in stable HeLa C1 cells also enables one to
visualise and quantify single secretory cargo fusion events at the
plasma membrane (see supplementary material Movie 2). However,
in primary MEFs isolated from the Htt140Q/140Q KI mouse or in
human patient fibroblasts, single cargo vesicles are smaller and
contain much less fluorescent content, making it challenging to
analyse the movement of single exocytic vesicles and to image
distinct post-Golgi cargo vesicles as well as single fusion events at
the plasma membrane in the TIRF field.
The crucial role of huntingtin in cargo transport in the early
secretory pathway (see Figs 1 and 4) was clearly demonstrated by
loss of wild-type huntingtin in HeLa cells after siRNA knockdown
and also by expression of only mutant 140Q huntingtin in primary
homozygous MEFs, leading to a kinetic delay in the movement of
cargo from the ER to the Golgi complex. Interestingly, fibroblasts
from a heterozygous individual with HD (HTT+/180Q), which still
express one wild-type copy of huntingtin, showed no significant
defect in the secretory pathway. The presence of one copy of wild-
type huntingtin seems to be sufficient for maintaining secretion, at
least in fibroblasts. In addition, the wild-type protein could also have
a protective role with respect to the defects caused by expression of
the mutant protein, as shown in a Drosophila model of HD (Arribat
et al., 2013). Moreover, the ratio of wild-type to mutant huntingtin
might be crucial in determining cell fate (Saleh et al., 2014) and,
thus, strategies to reduce mutant huntingtin levels are being
developed (Stanek et al., 2014).
In neuronal cells, in contrast to fibroblasts, the distances for cargo
to be transported between the ER, Golgi and plasma membrane are
extremely large and, therefore, a slight impairment in the efficiency
of delivery is likely to result in major defects in protein secretion,
which might contribute to the disease pathology associated with
reduced BDNF secretion in HD (Wang et al., 2012; Zala et al., 2008;
Pineda et al., 2009; Gauthier et al., 2004). Neuronal membrane
trafficking is believed to occur via the same basic membrane
compartments as those present in non-neuronal cells; however, the
polarised nature of nerve cells and the distinct morphology of long
cell projections in the form of axons and dendrites is linked to a
more complex organisation and distribution of these compartments.
We tested whether the reporter molecule GFP-hGH could be used
to measure the rate of exocytosis in primary cortical neurons but,
due to the toxicity of the reporter construct and the specialised
neuronal morphology, it was extremely difficult to measure the rate
of transport between the ER and the Golgi complex.
In summary, this novel regulated exocytosis assay has allowed us
to demonstrate the requirement for huntingtin at several steps along
the secretory pathway. In fibroblasts, the complete absence of wild-
type huntingtin in homozygous Htt140Q/140Q KI MEFs and after HTT
siRNA knockdown in HeLa cells reduces protein secretion. In
fibroblasts from a heterozygous individual with HD (HTT+/180Q), one
copy of huntingtin is sufficient to support cargo delivery in the
exocytic pathway. The majority of cell types are most likely able to
compensate for a slight reduction in secretory efficiency; however,
the striatal neurons most affected in HD might be particularly
susceptible to alterations in the trafficking of cargo, such as
receptors and transporters that are vital for neuronal cell survival.
This study suggests a crucial function for wild-type huntingtin that
cannot be fulfilled by the mutant protein and, thus, these results
could have important implications for therapies that aim to reduce
levels of mutant huntingtin.
MATERIALS AND METHODS
Antibodies
The following antibodies were used: anti-huntingtin (1HU-4C8; Millipore);
anti-optineurin (Sahlender et al., 2005); anti-GFP (Invitrogen); anti-GM130
(BD Biosciences); anti-DIC (MAB1618; Chemicon); a mouse monoclonal
to tubulin (Sigma).
Constitutive secretion assay
The constitutive secretion assay was generated by modifying the RPD
Regulated Secretion/Aggregation Kit (Ariad Pharmaceuticals, Cambridge,
MA) as described previously (Gordon et al., 2010; Bond et al., 2011). A
stable HeLaM cell line, termed HeLa C1, was generated and single clones
with moderate expression levels of the secretory cargo were selected for
further use. Secretion of the reporter construct was initiated by addition of
1 μM AP21998, a ligand that binds to the aggregation domains and thereby
solubilises the reporter molecule and promotes exit from the ER.
Cell culture, transfection and siRNA
The stable HeLa C1 cell line was grown in Dulbecco’s modified Eagle
medium (DMEM; Sigma, UK) supplemented with 10% fetal bovine serum
(FBS), 2 mM L-glutamine, penicillin/streptomycin (Sigma-Aldrich, UK)
and puromycin (1.66 μg/ml) at 37°C and 5% CO2. Human fibroblasts from
a healthy control (GM23976) and an individual with juvenile-onset HD
with a 180Q expansion (Sathasivam et al., 1997) (GM09197; HTT+/180Q)
were obtained from Coriell Cell Repositories and cultured in Minimum
Essential Medium (MEM) with Earl’s salts, non-essential amino acids, and
sodium bicarbonate (M5650; Sigma) supplemented with 15% FBS and
2 mM L-glutamine at 37°C and 5% CO2. Mouse embryonic fibroblasts
(MEFs) were established from wild-type and Htt140Q/140Q embryos at day
E17/18 of development. For preparation of fibroblasts, skin, limbs and
muscle tissue was dissected from the embryos, minced and incubated for
20 min at 37°C with trypsin containing 300 U/ml DNase (Invitrogen).
After addition of growth medium (DMEM with 10% FBS, glutamine,
penicillin and streptomycin), the digested tissue was dissociated using a
glass Pasteur pipette, centrifuged, resuspended in growth media and plated
onto tissue-culture treated dishes.
All siRNA oligos were obtained from Dharmacon. ON-TARGETplus
SMARTpool oligos (or individual siRNA oligos 1 and 2 against HTT) were
used to knock down huntingtin or dynein intermediate chain. For efficient
knockdown, HeLa C1 cells were transfected twice with four siRNA oligos
on day 1 and 3 using OligofectAMINE (Invitrogen). On day 5, cells were
processed for corresponding assays and the efficiency of protein depletion
was assessed by western blotting.
HeLa C1 cells were transfected with the GalT-mRFP plasmid (provided
by Dr G. Patterson, Lippincott-Schwartz Lab, National Institute of Child
Health and Human Development, MD) using FuGENE 6 (Roche
Diagnostics) according to the manufacturer’s instructions.
Immunofluorescence
For immunofluorescence, primary MEFs, human fibroblasts or HeLa C1
cells were grown on coverslips, transfected with the corresponding plasmids
and, 24 hours later, were fixed with 4% PFA, permeabilised with 0.1%
Triton X-100, blocked with 1% BSA in PBS and processed for indirect
immunofluorescence using primary antibodies (specified in the figure
legends) and secondary antibodies coupled with Alexa Fluor 488 or Alexa
Fluor 568 (Molecular Probes). After mounting, cells were imaged using a
Zeiss LSM710 confocal microscope.
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Spinning-disk microscopy and TIRF microscopy
For live-cell TIRF or spinning-disk microscopy studies, cells were grown
on 25-mm round coverslips (VWR International, UK) and imaged at 37°C
in CO2-independent medium (Invitrogen, UK). Images were obtained on a
Zeiss microscope equipped with spinning disk and TIRF attachment (Carl
Zeiss, Inc., UK). Images were acquired with a Hamamatsu Photonics EM-
CCD Digital Camera (Hamamatsu, Japan) and Zeiss Zen imaging software
(Carl Zeiss, Inc., UK). Volocity analysis software (Improvision, UK) was
used to quantify the rate of transfer of the reporter molecule from the ER to
the Golgi complex in spinning-disk videos. Imaris vesicle tracking software
(Bitplane) was used to quantify the total number of vesicles travelling
through 6×6-μm areas between the Golgi complex and the plasma
membrane.
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